Quantum BioPharma Ltd.
QNTMHealthcare|Biotechnology|CA
$2.10
-0.01 (-0.24%)
DCF Value
$0.09
Tangible Book / Share
$0.27
Cash / Share
$1.46
Financials
Financial Snapshot
Market Cap
$13.5M
Enterprise Value
$10.9M
Revenue (TTM)
$0.00
Net Income (TTM)
-$24.9M
Cash & Investments
$9.7M
Net Cash
$8.8M
Free Cash Flow (TTM)
-$5.4M
Operating CF (TTM)
-$5.4M
Debt/Equity
0.12
Cash Runway & Burn Rate
Cash on Hand
$9.7M
Quarterly Burn
$1.4M
Monthly Burn
$451.4K
Est. Runway
~7.2 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $7.1K | $3.8M | $15.5M | $6.0M | $17.5M | $35.4M | $17.0M | $3.5M | $7.2M | $6.2M | $9.7M | |
| Operating Cash Flow | -$27.2K | -$119.2K | -$13.6M | -$13.7M | -$19.1M | -$20.7M | -$28.3M | -$10.8M | -$6.9M | -$8.4M | -$5.4M | |
| Free Cash Flow | -$27.2K | -$6.2M | -$16.5M | -$14.0M | -$19.1M | -$21.2M | -$28.7M | -$10.8M | -$6.9M | -$8.4M | -$5.4M | |
| Capital Expenditure | $0.00 | -$6.1M | -$3.0M | -$293.1K | $0.00 | -$500.0K | -$364.0K | $0.00 | $0.00 | $0.00 | -$6.00 | |
| Financing Cash Flow | $34.4K | $10.0M | $32.9M | $4.0M | $24.2M | $38.2M | -$2.1M | -$3.1M | $11.6M | $6.2M | $11.0M |
R&D Spending
R&D (TTM)
$1.6M
R&D Intensity
—
R&D Growth vs Prior
-43.5%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $20.6K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $0.00 | $0.00 | $0.00 | $0.00 | $7.8M | $6.3M | $6.9M | $3.9M | $6.1M | $2.8M | $1.6M | |
| R&D % of Revenue | — | 0.0% | — | — | — | — | — | — | — | — | — | |
| SG&A | $29.6K | $2.8M | $17.5M | $20.5M | $18.1M | $23.4M | $16.0M | $13.2M | $9.3M | $12.0M | $10.1M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $20.6K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $0.00 | $0.00 | $182.6K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $250.8K | |
| Gross Profit | $0.00 | $20.6K | -$182.6K | -$2.6M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$250.8K | |
| R&D | $0.00 | $0.00 | $0.00 | $0.00 | $7.8M | $6.3M | $6.9M | $3.9M | $6.1M | $2.8M | $1.6M | |
| SG&A | $29.6K | $2.8M | $17.5M | $20.5M | $18.1M | $23.4M | $16.0M | $13.2M | $9.3M | $12.0M | $10.1M | |
| Operating Income | $0.00 | -$2.8M | $0.00 | -$30.6M | -$30.7M | -$33.7M | -$27.4M | -$23.8M | -$16.1M | -$15.3M | -$1.9M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $155.3K | $235.6K | $69.4K | $48.8K | $299.00 | $47.6K | $618.6K | $382.7K | |
| Pretax Income | -$29.6K | -$2.8M | -$16.7M | -$46.5M | -$28.5M | -$33.9M | -$26.7M | -$18.2M | -$14.9M | -$27.0M | -$25.0M | |
| Net Income | -$29.6K | -$2.8M | -$22.6M | -$39.1M | -$31.8M | -$35.3M | -$23.6M | -$17.9M | -$14.2M | -$26.2M | -$24.9M | |
| EPS (Diluted) | -0.29 | -27.75 | -183.54 | -360.45 | -171.62 | -65.63 | -39.62 | -29.39 | -12.49 | -8.11 | -5.65 | |
| EBITDA | -$29.6K | -$2.8M | -$16.5M | -$32.0M | -$24.3M | -$29.8M | -$22.1M | -$15.7M | -$14.4M | -$25.8M | -$23.7M | |
| Shares Out. (M) | 0.10 | 0.10 | 0.09 | 0.11 | 0.19 | 0.54 | 0.60 | 0.61 | 1.14 | 3.29 | 6.65 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $7.1K | $3.8M | $15.5M | $6.0M | $17.5M | $35.3M | $17.0M | $2.8M | $6.0M | $1.9M | $3.6M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $158.0K | $23.2K | $756.1K | $1.2M | $4.3M | $6.1M | |
| Total Current Assets | $7.1K | $4.3M | $16.6M | $8.6M | $26.9M | $45.9M | $17.9M | $11.1M | $12.1M | $6.5M | $9.9M | |
| Total Assets | $7.1K | $10.9M | $38.7M | $43.2M | $42.0M | $63.0M | $38.4M | $17.5M | $17.1M | $11.1M | $14.4M | |
| Total Current Liabilities | $61.4K | $1.0M | $1.3M | $6.8M | $5.6M | $8.7M | $7.8M | $4.6M | $6.7M | $6.0M | $8.3M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $61.4K | $1.0M | $1.3M | $6.9M | $5.7M | $8.8M | $7.9M | $4.6M | $6.7M | $6.0M | $8.3M | |
| Stockholders' Equity | -$54.3K | $9.9M | $37.5M | $36.3M | $36.3M | $54.1M | $30.5M | $13.2M | $11.5M | $6.9M | $7.9M | |
| Retained Earnings | -$1.3M | -$3.3M | -$19.5M | -$59.1M | -$90.9M | -$126.2M | -$144.2M | -$157.9M | -$172.1M | -$197.9M | -$214.8M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$27.2K | -$119.2K | -$13.6M | -$13.7M | -$19.1M | -$20.7M | -$28.3M | -$10.8M | -$6.9M | -$8.4M | -$5.4M | |
| Capital Expenditure | $0.00 | -$6.1M | -$3.0M | -$293.1K | $0.00 | -$500.0K | -$364.0K | $0.00 | $0.00 | $0.00 | -$6.00 | |
| Free Cash Flow | -$27.2K | -$6.2M | -$16.5M | -$14.0M | -$19.1M | -$21.2M | -$28.7M | -$10.8M | -$6.9M | -$8.4M | -$5.4M | |
| Investing Cash Flow | $0.00 | -$6.1M | -$7.3M | -$230.9K | $6.5M | $269.0K | $12.1M | -$269.6K | -$1.5M | -$2.0M | -$3.4M | |
| Financing Cash Flow | $34.4K | $10.0M | $32.9M | $4.0M | $24.2M | $38.2M | -$2.1M | -$3.1M | $11.6M | $6.2M | $11.0M | |
| Issuance of Stock | $66.5K | $11.0M | $33.0M | $3.4M | $25.1M | $38.3M | $0.00 | $34.00 | $10.7M | $538.9K | $8.1M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$1.9M | -$3.0M | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $0.00 | -$42.3K | -$986.6K | -$129.3K | -$143.1K | -$189.1K | $948.3K | $5.2M | $1.9M | |
| Stock Based Comp. | $0.00 | $2.4M | $4.7M | $12.1M | $8.1M | $7.4M | $1.5M | $3.8M | $152.2K | $2.9M | $2.7M | |
| Net Change in Cash | $7.1K | $3.7M | $12.0M | -$9.9M | $11.6M | $17.7M | -$18.3M | -$14.2M | $3.2M | -$4.1M | $2.1M |
Dilution Tracker
Shares outstanding grew 1673.4% over 5 years — significant dilution
Shares Outstanding
6M
5-Year Share Growth
+1673.4%
Stock Issuance (TTM)
$8.1M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.10 | 0.10 | 0.09 | 0.11 | 0.19 | 0.54 | 0.60 | 0.61 | 1.14 | 3.29 | 6.65 | |
| Change vs Prior % | — | 0.0% | -10.1% | 19.5% | 70.7% | 190.1% | 10.8% | 2.2% | 86.7% | 189.0% | 102.4% | |
| Stock Issuance | $66.5K | $11.0M | $33.0M | $3.4M | $25.1M | $38.3M | $0.00 | $34.00 | $10.7M | $538.9K | $8.1M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$1.9M | -$3.0M | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $2.4M | $4.7M | $12.1M | $8.1M | $7.4M | $1.5M | $3.8M | $152.2K | $2.9M | $2.7M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | — | 100.0% | — | — | — | — | — | — | — | — | — | |
| Operating Margin % | — | -13586.0% | — | — | — | — | — | — | — | — | — | |
| Net Margin % | — | -13586.0% | — | — | — | — | — | — | — | — | — | |
| EBITDA Margin % | — | -13586.0% | — | — | — | — | — | — | — | — | — | |
| FCF Margin % | — | -30079.7% | — | — | — | — | — | — | — | — | — | |
| ROE % | 54.6% | -28.4% | -60.4% | -107.9% | -87.6% | -65.2% | -77.3% | -135.2% | -123.7% | -378.7% | -413.1% | |
| ROA % | -415.1% | -25.8% | -58.4% | -90.5% | -75.8% | -56.0% | -61.5% | -102.4% | -83.0% | -235.0% | -173.1% | |
| ROIC % | 0.0% | -28.4% | 0.0% | -80.8% | -83.4% | -61.7% | -88.3% | -179.6% | -143.2% | -219.7% | -27.1% | |
| R&D / Revenue % | — | 0.0% | — | — | — | — | — | — | — | — | — |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | -100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | -985.2% | -1350.4% | 100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | 0.0% | 0.0% | 100.0% | 0.0% | -0.4% | -9.9% | 18.7% | 13.3% | 32.2% | 5.2% | |
| Net Income | 9.7% | -9360.0% | -707.7% | -72.8% | 18.7% | -11.0% | 33.1% | 24.2% | 20.7% | -84.3% | |
| EPS (Diluted) | 9.4% | -9469.0% | -561.4% | -96.4% | 52.4% | 61.8% | 39.6% | 25.8% | 57.5% | 35.1% | |
| Operating Cash Flow | -42838.4% | -337.5% | -11290.9% | -1.0% | -39.5% | -8.4% | -36.6% | 61.8% | 36.5% | -21.9% | |
| Free Cash Flow | -42838.4% | -22682.3% | -166.5% | 15.3% | -36.6% | -11.1% | -35.1% | 62.3% | 36.5% | -21.9% | |
| R&D Expense | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -19.2% | 9.2% | -44.2% | 57.6% | -54.6% | |
| SG&A Expense | -9.7% | 9429.6% | 519.4% | 17.2% | -11.6% | 29.0% | -31.6% | -17.4% | -29.5% | 29.0% | |
| Total Assets | 230.4% | 152323.8% | 256.2% | 11.5% | -2.9% | 50.0% | -39.0% | -54.5% | -2.0% | -34.9% | |
| Book Value / Share | 7.0% | 18281.0% | 322.0% | -19.0% | -41.4% | -48.6% | -49.1% | -58.6% | -56.7% | -83.1% | |
| Debt | -100.0% | 0.0% | 0.0% | 0.0% | -67.9% | 8.9% | -7.1% | -34.3% | 143.2% | 127.0% | |
| Diluted Shares | 0.0% | 0.0% | -10.1% | 19.5% | 70.7% | 190.1% | 10.8% | 2.2% | 86.7% | 189.0% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B1.76
10Y Low / Med / High0.36 / 1.06 / 11.50
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$0.09
Tangible Book / Share
$0.27
Net Current Assets / Share
$0.26
Graham Net-Net
$0.23
Cash / Share
$1.46
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -3874.45 | -40.49 | -15.23 | -0.98 | -0.59 | -1.01 | -1.29 | -2.03 | -0.29 | -0.90 | -0.37 | |
| P/S Ratio | 0.00 | 5500.85 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | -2090.03 | 11.50 | 6.78 | 1.06 | 0.52 | 0.66 | 1.00 | 2.75 | 0.36 | 3.47 | 1.76 | |
| EV/EBITDA | -3830.01 | -39.14 | -14.42 | -1.06 | -0.07 | -0.03 | -0.64 | -2.16 | 0.07 | -0.93 | -0.46 | |
| EV/Revenue | 0.00 | 5318.14 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-25.36
Distress
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $15.0M | $26.3M | $48.6M |
| Net Income | -$6.1M | $0.00 | $0.00 |
| EPS | $-1.85 | $0.00 | $0.00 |
| # Analysts (EPS) | 1 | 0 | 0 |